Renal Cancer - Results from #520

TFE3-splicing factor fusions represent functional drivers and druggable targets in translocation renal cell carcinoma. January 30, 2024

Investigation of clear cell renal cell carcinoma grades using diffusion-relaxation correlation spectroscopic imaging with optimized spatial-spectrum analysis. January 30, 2024

Urologist-level variation in the management of T1a renal cell carcinoma: A population-based cohort study. January 29, 2024

The Relationship Between Health-Related Quality of Life and Overall Survival in Patients With Advanced Renal Cell Carcinoma in CheckMate 214. January 29, 2024

Phase II Trial of Stereotactic Ablative Radiation for Oligoprogressive Metastatic Kidney Cancer. January 27, 2024

Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial. January 26, 2024

Cabozantinib and Axitinib After Vascular Endothelial Growth Factor Therapy in Patients with Advanced Renal Cell Carcinoma: A Retrospective Cohort Study from England. January 26, 2024

Skeletal muscle and visceral adipose radiodensities are pre-surgical, non-invasive markers of aggressive kidney cancer. January 25, 2024

Established and emerging biomarkers of immunotherapy in renal cell carcinoma. January 25, 2024

Retrospective Multicenter Analysis of Prognostic Risk Factors for One Year Recurrence in Patient With Renal Cell Carcinoma After Partial or Radical Nephrectomy: Results of Korean Renal Cancer Study Group (KRoCS) Database. January 24, 2024

Navigating the ICI Combination Treatment Journey: Patterns of Response and Progression to First-Line ICI-Based Combination Treatment in Metastatic Renal Cell Carcinoma. January 24, 2024

Analysis of the immunological markers BTLA, TIM-3, and PD-L1 at the invasion front and tumor center in clear cell renal cell carcinoma. January 23, 2024

A review of stereotactic ablative radiotherapy for nonmetastatic renal cell carcinoma. January 23, 2024

Qualitative and quantitative characteristics of CEUS for renal cell carcinoma and angiomyolipoma: a narrative review. January 22, 2024

Prognostic outcomes in patients with metastatic renal cell carcinoma receiving second-line treatment with tyrosine kinase inhibitor following first-line immune-oncology combination therapy. January 22, 2024

Immune Checkpoint Inhibitors in Cancer Therapy. January 22, 2024

Computed tomography for visible haematuria - a single nephrographic phase is sufficient for detecting renal cell carcinoma. January 19, 2024

PET/Computed Tomography Transformation of Oncology: Kidney and Urinary Tract Cancers. January 19, 2024

Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study. January 18, 2024

Immunomodulatory response to neoadjuvant nivolumab in non-metastatic clear cell renal cell carcinoma. January 18, 2024

Page 27 of 456